Refining the Maintenance Protocol for Advanced Ovarian Cancer

CME: 1.0

March 10, 2021
KEYWORDS Primary Care
/ Print / Reprints /
| Share More
/ Text Size+

The recent availability of PARP inhibitors as maintenance therapy in the first-line setting allows clinicians to offer improved treatment options to their patients with ovarian cancer.

Post a comment to this article